
    
      After signing Institutional Review Board (IRB) approved consent, subjects with metastatic
      cancer will be enrolled. The vaccine doses will be prepared and dispensed by the University
      of Arkansas for Medical Sciences (UAMS) Pharmacy following the manufacturer's instructions.
      Subjects will receive 1.0 mL subcutaneous injections of the vaccine on 4 separate occasions.
      The vaccine will be administered at rotating sites on the limbs or abdomen. The study will
      last approximately 12 months.
    
  